GenapSys, Inc. is committed to a new era of applied genomic testing and a new paradigm for medical sequencing. We are developing a cost-disruptive, easy-to-use genomic diagnostic system based on our simple label-free proprietary GENIUS™ technology which delivers 100x improvement in cost and speed. These innovations will enable a new era of medicine through the widespread acquisition of genomic data for research and testing of genetic disease, cancer, and microbes.
GenapSys is developing a disruptive DNA-sequencing technology that enables fast, accurate, and ultra-low cost genetic testing. Although DNA Sequencing has led to rapid advancements in the field of medicine and healthcare, costs, turnaround times, and workflow inhibit mass use, especially in the clinical realm. The GenapSys sample-to-answer instrument provides a 100x solution – with orders of magnitude improvement across all dimensions of cost (including the cost of the instrument, cost per test, cost of labor, and cost of informatics), speed, and an automated sample-in data-out workflow. These orders of magnitude improvements will open up new markets and enable the democratization of sequencing on a mass scale.
Genapsys was founded by Dr. Hesaam Esfandyarpour, and incubated over 6 years at the Stanford Genome Technology Center. Coming from a completely different background – getting his PhD in Electrical Engineering at Stanford at the time – Dr. Esfandyarpour was able to conceive a novel and far higher efficiency method for DNA Sequencing. Instead of the leading optical technologies, the GenapSys system centers around a pure electronic chip – detecting the main reaction in a simple, elegant, and ultra-low cost fashion. Since incorporation in 2010, GenapSys has built a stellar team, including both scientists, chemists, engineers, and informaticians, mostly graduates of Stanford, Harvard, MIT, CalTech, UC Berkeley, and similar. GenapSys has set up headquarters in Redwood City, CA. The company was recently awarded an additional $4M grant from NHGRI (representing over 20% of the $18.7M allocated for projects to improve gene sequencing) in September 2012.